New Clinical Subtypes of Parkinson Disease and Their I

JAMA Neurology 72, 863

DOI: 10.1001/jamaneurol.2015.0703

Citation Report

#	Article	IF	CITATIONS
2	Aberrant Brain Network Efficiency in Parkinson's Disease Patients with Tremor: A Multi-Modality Study. Frontiers in Aging Neuroscience, 2015, 7, 169.	1.7	32
3	Autonomic dysfunction in subjects at high risk for Parkinson's disease. Journal of Neurology, 2015, 262, 2643-2652.	1.8	17
4	Clinical Determinants of Progression of Parkinson Disease. JAMA Neurology, 2015, 72, 859.	4.5	4
5	REM sleep behavior disorder and neuropathology in Parkinson's disease. Movement Disorders, 2015, 30, 1413-1417.	2.2	128
6	Disease-Modifying Drugs in Parkinson's Disease. Drugs, 2015, 75, 2065-2071.	4.9	29
7	Technology in Parkinson's disease: Challenges and opportunities. Movement Disorders, 2016, 31, 1272-1282.	2.2	464
8	Motor subtype in Parkinson's disease: Different disorders or different stages of disease?. Movement Disorders, 2016, 31, 957-961.	2.2	86
9	Nonmotor features of Parkinson's disease subtypes. Movement Disorders, 2016, 31, 1095-1102.	2.2	254
10	The Evolution of REM Sleep Behavior Disorder in Early Parkinson Disease. Sleep, 2016, 39, 1737-1742.	0.6	89
11	Self-Perceived Pre-Motor Symptoms Load in Patients with Parkinson's Disease: A Retrospective Study. Journal of Parkinson's Disease, 2016, 6, 183-190.	1.5	12
12	â€~Under pressure': is there a link between orthostatic hypotension and cognitive impairment in α-synucleinopathies?. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1311-1321.	0.9	75
13	Clinical subtypes and genetic heterogeneity: of lumping and splitting in Parkinson disease. Current Opinion in Neurology, 2016, 29, 727-734.	1.8	55
14	The nonmotor features of Parkinson's disease: pathophysiology and management advances. Current Opinion in Neurology, 2016, 29, 467-473.	1.8	44
15	Vascular Risk Factors and Cognition in Parkinson's Disease. Journal of Alzheimer's Disease, 2016, 51, 563-570.	1.2	49
16	Clinical clusters and dopaminergic dysfunction in de-novo Parkinson disease. Parkinsonism and Related Disorders, 2016, 28, 137-140.	1.1	62
17	Challenges in detecting disease modification in Parkinson's disease clinical trials. Parkinsonism and Related Disorders, 2016, 32, 1-11.	1.1	52
18	Patterns of cortical thinning in nondemented Parkinson's disease patients. Movement Disorders, 2016, 31, 699-708.	2.2	71
19	Treatment of Sleep Disorders in Dementia. Current Treatment Options in Neurology, 2016, 18, 40.	0.7	81

#	ARTICLE	IF	CITATIONS
20	Risk Factor Profile in Parkinson's Disease Subtype with REM Sleep Behavior Disorder. Journal of Parkinson's Disease, 2016, 6, 231-237.	1.5	21
21	Orthostatic hypotension predicts motor decline in early Parkinson disease. Parkinsonism and Related Disorders, 2016, 32, 127-129.	1.1	20
22	Orthostatic hypotension in Parkinson's disease: Does it matter if asymptomatic?. Parkinsonism and Related Disorders, 2016, 33, 65-71.	1.1	68
23	Parkinsonism. Seminars in Neurology, 2016, 36, 330-334.	0.5	43
24	Visual dysfunction in Parkinson's disease. Brain, 2016, 139, 2827-2843.	3.7	320
25	Resting state MRI: a new marker of prodromal neurodegeneration?. Brain, 2016, 139, 2106-2108.	3.7	19
26	Progresi $\tilde{A}^3$ n cl $\tilde{A}$ nica de la enfermedad de Parkinson: an $\tilde{A}_i$ lisis retrospectivo en un consultorio especializado en trastornos del movimiento. Neurologia Argentina, 2016, 8, 258-262.	0.1	1
27	Advances in markers of prodromal Parkinson disease. Nature Reviews Neurology, 2016, 12, 622-634.	4.9	272
28	Severe Brain Metabolic Decreases Associated with REM Sleep Behavior Disorder in Dementia with Lewy Bodies. Journal of Alzheimer's Disease, 2016, 52, 989-997.	1.2	15
29	Functional neuroimaging and clinical features of drug naive patients with de novo Parkinson's disease and probable RBD. Parkinsonism and Related Disorders, 2016, 29, 47-53.	1.1	57
30	Reduced intraepidermal nerve fiber density in patients with REM sleep behavior disorder. Parkinsonism and Related Disorders, 2016, 29, 10-16.	1.1	29
31	Speech prosody impairment predicts cognitive decline in Parkinson's disease. Parkinsonism and Related Disorders, 2016, 29, 90-95.	1.1	43
32	Challenges of modifying disease progression in prediagnostic Parkinson's disease. Lancet Neurology, The, 2016, 15, 637-648.	4.9	78
33	Electroencephalographic prodromal markers of dementia across conscious states in Parkinson's disease. Brain, 2016, 139, 1189-1199.	3.7	60
34	Voice changes in prodromal Parkinson's disease: Is a new biomarker within earshot?. Sleep Medicine, 2016, 19, 148-149.	0.8	5
35	Screening for prodromal Parkinson's disease in the general community: a sleep-based approach. Sleep Medicine, 2016, 21, 101-105.	0.8	48
36	Integrating Patient Concerns into Parkinson's Disease Management. Current Neurology and Neuroscience Reports, 2017, 17, 3.	2.0	44
37	The sleeping brain in Parkinson's disease: A focus on REM sleep behaviour disorder and related parasomnias for practicing neurologists. Journal of the Neurological Sciences, 2017, 374, 32-37.	0.3	12

#	ARTICLE	IF	Citations
38	Inflammatory profile discriminates clinical subtypes in <i>LRRK2</i> àê€essociated Parkinson's disease. European Journal of Neurology, 2017, 24, 427.	1.7	56
40	Personality and addictive behaviours in early Parkinson's disease and REM sleep behaviour disorder. Parkinsonism and Related Disorders, 2017, 37, 72-78.	1.1	27
41	Association between cognitive impairment and urinary dysfunction in Parkinson's disease. Journal of Neural Transmission, 2017, 124, 543-550.	1.4	10
42	Validation of the MDS research criteria for prodromal Parkinson's disease: Longitudinal assessment in a REM sleep behavior disorder (RBD) cohort. Movement Disorders, 2017, 32, 865-873.	2.2	102
43	Clinical Characteristics of Parkinson's Disease Developed from Essential Tremor. Journal of Parkinson's Disease, 2017, 7, 369-376.	1.5	13
44	Redefinition of Parkinson's Disease. Neurology International Open, 2017, 1, E65-E70.	0.4	0
45	Application of the movement disorder society prodromal Parkinson's disease research criteria in 2 independent prospective cohorts. Movement Disorders, 2017, 32, 1025-1034.	2.2	75
46	Sleep Disturbances in the Prodromal Stage of Parkinson Disease. Current Treatment Options in Neurology, 2017, 19, 22.	0.7	43
47	Sleep <scp>D</scp> isorders and <scp>RBD</scp> : What <scp>W</scp> ould <scp>J</scp> ames <scp>P</scp> arkinson <scp>T</scp> hink?. Movement Disorders, 2017, 32, 705-707.	2.2	0
48	Immunopathology of the Nervous System. Molecular and Integrative Toxicology, 2017, , 123-219.	0.5	0
49	Clinical criteria for subtyping Parkinson's disease: biomarkers and longitudinal progression. Brain, 2017, 140, 1959-1976.	3.7	391
50	Baseline motor findings and Parkinson disease prognostic subtypes. Neurology, 2017, 89, 138-143.	1.5	33
51	Global, Yet Incomplete Overview of Cohort Studies in Parkinson's disease. Journal of Parkinson's Disease, 2017, 7, 423-432.	1.5	25
53	Rapid Eye Movement Sleep Behavior Disorder. Chest, 2017, 152, 650-662.	0.4	20
54	Motor and non-motor symptoms in old-age onset Parkinson's disease patients. Journal of Neural Transmission, 2017, 124, 863-867.	1.4	9
55	Subtypes of Parkinson's Disease: What Do They Tell Us About Disease Progression?. Current Neurology and Neuroscience Reports, 2017, 17, 34.	2.0	100
56	Insomnia and somnolence in idiopathic RBD: a prospective cohort study. Npj Parkinson's Disease, 2017, 3, 9.	2.5	39
57	Dementia Predictors in Parkinson Disease: A Validation Study. Journal of Parkinson's Disease, 2017, 7, 159-162.	1.5	38

#	Article	IF	CITATIONS
58	Anxiety is associated with cognitive impairment in newly-diagnosed Parkinson's disease. Parkinsonism and Related Disorders, 2017, 36, 63-68.	1.1	50
59	Cognitive changes in prodromal Parkinson's disease: A review. Movement Disorders, 2017, 32, 1655-1666.	2.2	82
60	Objective Measurement and Monitoring of Nonmotor Symptoms in Parkinson's Disease. International Review of Neurobiology, 2017, 133, 347-387.	0.9	5
61	Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls. Neurology, 2017, 89, 1959-1969.	1.5	121
62	Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy. Movement Disorders, 2017, 32, 1264-1310.	2.2	608
63	Nonmotor Subtyping in Parkinson's Disease. International Review of Neurobiology, 2017, 133, 447-478.	0.9	18
64	A user's guide for αâ€synuclein biomarker studies in biological fluids: Perianalytical considerations. Movement Disorders, 2017, 32, 1117-1130.	2.2	54
65	Merging Clinical and Imaging Biomarkers to Tackle Parkinson's Disease. Movement Disorders Clinical Practice, 2017, 4, 652-662.	0.8	6
66	Rapid eye movement sleep behaviour disorder and striatal dopamine depletion in patients with Parkinson's disease. European Journal of Neurology, 2017, 24, 1314-1319.	1.7	26
67	Predicting rapid progression of Parkinson's Disease at baseline patients evaluation., 2017, 2017, 3898-3901.		7
68	Domperidone for Hypotension in Parkinson's Disease: A Systematic Review. Journal of Parkinson's Disease, 2017, 7, 603-617.	1.5	11
69	Prediction of cognitive worsening in de novo Parkinson's disease: Clinical use of biomarkers. Movement Disorders, 2017, 32, 1738-1747.	2.2	43
70	REM Sleep Behavior Disorder and Cognitive Impairment in Parkinson's Disease. Sleep, 2017, 40, .	0.6	115
71	Association of Autonomic Dysfunction With Disease Progression and Survival in Parkinson Disease. JAMA Neurology, 2017, 74, 970.	4.5	162
72	Common variant rs356182 near SNCA defines a Parkinson's disease endophenotype. Annals of Clinical and Translational Neurology, 2017, 4, 15-25.	1.7	40
74	Neuropathology of Nonmotor Symptoms of Parkinson's Disease. International Review of Neurobiology, 2017, 133, 13-62.	0.9	39
75	Joint prediction of multiple scores captures better individual traits from brain images. NeuroImage, 2017, 158, 145-154.	2.1	35
76	$\hat{l}_{\pm}$ -Synuclein in the colon and premotor markers of Parkinson disease in neurologically normal subjects. Neurological Sciences, 2017, 38, 171-179.	0.9	14

#	Article	IF	Citations
77	Neuropsychiatric Predictors of Cognitive Decline in Parkinson Disease: A Longitudinal Study. American Journal of Geriatric Psychiatry, 2017, 25, 279-289.	0.6	38
78	Constipation in parkinson's disease: Subjective symptoms, objective markers, and new perspectives. Movement Disorders, 2017, 32, 94-105.	2.2	127
79	Prevalence of rapid eye movement sleep behavior disorder (RBD) in Parkinson's disease: a meta and meta-regression analysis. Neurological Sciences, 2017, 38, 163-170.	0.9	86
80	Clinical utility of DaTscanâ,,¢ imaging in the evaluation of patients with parkinsonism: a US perspective. Expert Review of Neurotherapeutics, 2017, 17, 219-225.	1.4	22
81	Latent Class Analysis in health research. Journal of Physiotherapy, 2017, 63, 55-58.	0.7	123
82	Molecular Imaging and Precision Medicine in Dementia and Movement Disorders. PET Clinics, 2017, 12, 119-136.	1.5	1
83	Normal †heart†in Parkinson's disease: is this a distinct clinical phenotype?. European Journal of Neurology, 2017, 24, 349-356.	1.7	49
84	Anosmia and Ageusia in Parkinson's Disease. International Review of Neurobiology, 2017, 133, 541-556.	0.9	71
85	Genetic Determinants of Parkinson's Disease: Can They Help to Stratify the Patients Based on the Underlying Molecular Defect?. Frontiers in Aging Neuroscience, 2017, 9, 20.	1.7	44
86	Earlier Intervention with Deep Brain Stimulation for Parkinson's Disease. Parkinson's Disease, 2017, 2017, 1-9.	0.6	20
87	Clinical utility and research frontiers of neuroimaging in movement disorders. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2017, 61, 372-385.	0.4	3
88	Nonmotor Aspects of Parkinson's Disease—How Do They Help Diagnosis?. International Review of Neurobiology, 2017, 133, 519-539.	0.9	7
89	Quality of Life and Nonmotor Symptoms in Parkinson's Disease. International Review of Neurobiology, 2017, 133, 499-516.	0.9	60
90	Heterogeneous pattern of autonomic dysfunction in Parkinson's disease. Journal of Neurology, 2018, 265, 933-941.	1.8	34
91	Facial emotion recognition in Parkinson's disease: A review and new hypotheses. Movement Disorders, 2018, 33, 554-567.	2.2	132
92	Assessing cognitive dysfunction in Parkinson's disease: An online tool to detect visuoâ€perceptual deficits. Movement Disorders, 2018, 33, 544-553.	2.2	25
93	The clinical relevance of cognitive impairment in REM sleep behavior disorder. Neurology, 2018, 90, 909-910.	1.5	4
94	Baseline symptoms and basal forebrain volume predict future psychosis in early Parkinson disease. Neurology, 2018, 90, e1618-e1626.	1.5	44

#	Article	IF	CITATIONS
95	Effects of transcranial pulsed electromagnetic field stimulation on quality of life in Parkinson's disease. European Journal of Neurology, 2018, 25, 963.	1.7	9
96	Sleep disorders and Parkinson disease; lessons from genetics. Sleep Medicine Reviews, 2018, 41, 101-112.	3.8	35
97	RBD: a red flag for cognitive impairment in Parkinson's disease?. Sleep Medicine, 2018, 44, 38-44.	0.8	33
98	Microstructural changes in patients with Parkinson disease and REM sleep behavior disorder: depressive symptoms versus non-depressed. Acta Neurologica Belgica, 2018, 118, 415-421.	0.5	17
99	Autonomic dysfunction in Parkinson's disease: A prospective cohort study. Movement Disorders, 2018, 33, 391-397.	2.2	108
100	Progression in the <i>LRRK2</i> -Associated Parkinson Disease Population. JAMA Neurology, 2018, 75, 312.	4.5	109
101	Prevalence and determinants of rapid eye movement sleep behavior disorder in the general population. Sleep, 2018, 41, .	0.6	163
102	Evaluation of the noradrenergic system in Parkinson's disease: an 11C-MeNER PET and neuromelanin MRI study. Brain, 2018, 141, 496-504.	3.7	135
103	High angular resolution diffusion imaging correlates of depression in Parkinson's disease: a connectometry study. Acta Neurologica Belgica, 2018, 118, 573-579.	0.5	9
104	Office-Based Screening for Dementia in Parkinson Disease. JAMA Neurology, 2018, 75, 704.	4.5	17
105	Abnormal Gray Matter Shape, Thickness, and Volume in the Motor Cortico-Subcortical Loop in Idiopathic Rapid Eye Movement Sleep Behavior Disorder: Association with Clinical and Motor Features. Cerebral Cortex, 2018, 28, 658-671.	1.6	51
106	Unlocking the mystery of biomarkers: A brief introduction, challenges and opportunities in Parkinson Disease. Parkinsonism and Related Disorders, 2018, 46, S15-S18.	1.1	14
107	Sleep and REM sleep behaviour disorder in Parkinson's disease with impulse control disorder. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 305-310.	0.9	29
108	Cardiac sympathetic denervation predicts PD in at-risk individuals. Parkinsonism and Related Disorders, 2018, 52, 90-93.	1.1	34
109	Noradrenergic Deficits in Parkinson Disease Imaged with $\langle \sup 11 \langle \sup \rangle C$ -MeNER. Journal of Nuclear Medicine, 2018, 59, 659-664.	2.8	40
110	Patterns of grey matter loss associated with motor subscores in early Parkinson's disease. NeuroImage: Clinical, 2018, 17, 498-504.	1.4	43
111	Sulfate radical oxidation combined with iron flocculation for upgrading biological effluent of coking wastewater. RSC Advances, 2018, 8, 38765-38772.	1.7	5
112	A Time-Sensitive Hybrid Learning Model for Patient Subgrouping. , 2018, , .		6

#	Article	IF	CITATIONS
113	Developing and validating Parkinson's disease subtypes and their motor and cognitive progression. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 1279-1287.	0.9	116
114	Serum Inflammatory Profile for the Discrimination of Clinical Subtypes in Parkinson's Disease. Frontiers in Neurology, 2018, 9, 1123.	1.1	19
115	Autonomic Symptoms Correlate with Non-Autonomic Non-Motor Symptoms and Sleep Problems in Patients with Parkinson's Disease. European Neurology, 2018, 80, 193-199.	0.6	18
116	Interaction Between Neuropsychiatric Symptoms and Cognitive Performance in Parkinson's Disease: What Do Clinical and Neuroimaging Studies Tell Us?. Current Neurology and Neuroscience Reports, 2018, 18, 91.	2.0	6
117	Excessive Daytime Sleepiness and REM Sleep Behavior Disorders in Parkinson's Disease: A Narrative Review on Early Intervention With Implications to Neuroprotection. Frontiers in Neurology, 2018, 9, 961.	1,1	13
118	Molecular Imaging of the Noradrenergic System in Idiopathic Parkinson's Disease. International Review of Neurobiology, 2018, 141, 251-274.	0.9	13
119	Predicting alpha-synuclein pathology by REM sleep behavior disorder diagnosis. Parkinsonism and Related Disorders, 2018, 55, 92-96.	1.1	19
120	In-vivo staging of pathology in REM sleep behaviour disorder: a multimodality imaging case-control study. Lancet Neurology, The, 2018, 17, 618-628.	4.9	228
121	Reproducibility of data-driven Parkinson's disease subtypes for clinical research. Parkinsonism and Related Disorders, 2018, 56, 102-106.	1.1	63
122	Diagnostic Criteria for Parkinson's Disease: From James Parkinson to the Concept of Prodromal Disease. Frontiers in Neurology, 2018, 9, 156.	1.1	136
123	Hypermetabolism in the cerebellum and brainstem and cortical hypometabolism are independently associated with cognitive impairment in Parkinson's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 2387-2395.	3.3	23
124	Microstructural Changes in Patients With Parkinson's Disease Comorbid With REM Sleep Behaviour Disorder and Depressive Symptoms. Frontiers in Neurology, 2018, 9, 441.	1.1	16
125	A decision support system based on rapid progression rules to enhance baseline evaluation of Parkinson's disease patients. , 2018, , .		1
126	Decisions about deep brain stimulation therapy in Parkinson's disease. Arquivos De Neuro-Psiquiatria, 2018, 76, 411-420.	0.3	7
127	Sleep in Parkinson's Disease with Impulse Control Disorder. Current Neurology and Neuroscience Reports, 2018, 18, 68.	2.0	6
128	Use of a Modified STROOP Test to Assess Color Discrimination Deficit in Parkinson's Disease. Frontiers in Neurology, 2018, 9, 765.	1.1	4
129	REM behavior disorder predicts motor progression and cognitive decline in Parkinson disease. Neurology, 2018, 91, e894-e905.	1.5	112
130	Importance of Balance-Gait Disorder as a Risk Factor for Cognitive Impairment, Dementia and Related Non-Motor Symptoms in Parkinson's Disease. Journal of Parkinson's Disease, 2018, 8, 539-552.	1.5	17

#	Article	IF	CITATIONS
131	Cognitive Impairment and Mortality in a Population-Based Parkinson's Disease Cohort. Journal of Parkinson's Disease, 2018, 8, 353-362.	1.5	16
132	Clinical Subtypes of Dementia with Lewy Bodies Based on the Initial Clinical Presentation. Journal of Alzheimer's Disease, 2018, 64, 505-513.	1.2	16
133	GBA-Associated Parkinson's Disease and Other Synucleinopathies. Current Neurology and Neuroscience Reports, 2018, 18, 44.	2.0	106
134	Objective intestinal function in patients with idiopathic REM sleep behavior disorder. Parkinsonism and Related Disorders, 2019, 58, 28-34.	1.1	18
135	Treatment options for postural instability and gait difficulties in Parkinson's disease. Expert Review of Neurotherapeutics, 2019, 19, 1229-1251.	1.4	22
136	Update of the MDS research criteria for prodromal Parkinson's disease. Movement Disorders, 2019, 34, 1464-1470.	2.2	435
137	REM sleep behavior disorder predicts functional dependency in early Parkinson's disease. Parkinsonism and Related Disorders, 2019, 66, 138-142.	1.1	9
140	Neurogenic Orthostatic Hypotension in Parkinson Disease: A Primer. Neurology and Therapy, 2019, 8, 307-324.	1.4	23
141	Assessment of a prognostic MRI biomarker in early de novo Parkinson's disease. NeuroImage: Clinical, 2019, 24, 101986.	1.4	26
142	Overall and Disease Related Mortality in Parkinson's Disease – a Longitudinal Cohort Study. Journal of Parkinson's Disease, 2019, 9, 767-774.	1.5	11
143	Brain-First versus Gut-First Parkinson's Disease: A Hypothesis. Journal of Parkinson's Disease, 2019, 9, S281-S295.	1.5	201
144	The relationship between environmental factors and different Parkinson's disease subtypes in Greece: Data analysis of the Hellenic Biobank of Parkinson's disease. Parkinsonism and Related Disorders, 2019, 67, 105-112.	1.1	21
145	Data-Driven Subtyping of Parkinson's Disease Using Longitudinal Clinical Records: A Cohort Study. Scientific Reports, 2019, 9, 797.	1.6	76
146	Cognitive behavioral therapy improves diverse profiles of depressive symptoms in Parkinson's disease. International Journal of Geriatric Psychiatry, 2019, 34, 722-729.	1.3	17
147	Modeling the frictional torque of a dry-lubricated tapered roller bearing considering the roller skewing. Friction, 2019, 7, 551-563.	3.4	15
148	Structural Imaging in Parkinson's Disease: New Developments. Current Neurology and Neuroscience Reports, 2019, 19, 50.	2.0	27
149	Alteration of Tremor Dominant and Postural Instability Gait Difficulty Subtypes During the Progression of Parkinson's Disease: Analysis of the PPMI Cohort. Frontiers in Neurology, 2019, 10, 471.	1.1	40
150	Orthostatic hypotension and REM sleep behaviour disorder: impact on clinical outcomes in α-synucleinopathies. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 1257-1263.	0.9	73

#	Article	IF	Citations
151	Neural correlates of early cognitive dysfunction in Parkinson's disease. Annals of Clinical and Translational Neurology, 2019, 6, 902-912.	1.7	17
152	Young-onset Parkinson's disease: Its unique features and their impact on quality of life. Parkinsonism and Related Disorders, 2019, 65, 39-48.	1.1	69
153	Evolution of prodromal Parkinson's disease and dementia with Lewy bodies: a prospective study. Brain, 2019, 142, 2051-2067.	3.7	215
154	Cortical thinning in patients with REM sleep behavior disorder is associated with clinical progression. Npj Parkinson's Disease, 2019, 5, 7.	2.5	40
155	Progression of Parkinson's disease patients' subtypes based on cortical thinning: 4-year follow-up. Parkinsonism and Related Disorders, 2019, 64, 286-292.	1.1	27
156	Heterogeneity in progression of prodromal features in Parkinson's disease. Parkinsonism and Related Disorders, 2019, 64, 275-279.	1.1	15
157	Sleep and risk of parkinsonism and Parkinson's disease: a population-based study. Brain, 2019, 142, 2013-2022.	3.7	63
158	Periventricular White Matter Abnormalities on Diffusion Tensor Imaging of Postural Instability Gait Disorder Parkinsonism. American Journal of Neuroradiology, 2019, 40, 609-613.	1.2	7
159	Brain atrophy in Parkinson's disease with polysomnography-confirmed REM sleep behavior disorder. Sleep, 2019, 42, .	0.6	41
161	Impulse Control Disorders in REM Sleep Behavior Disorder. Current Treatment Options in Neurology, 2019, 21, 23.	0.7	7
162	Higher probability of prodromal Parkinson disease is related to lower cognitive performance. Neurology, 2019, 92, e2261-e2272.	1.5	34
163	Clinical progression in Parkinson's disease with features of REM sleep behavior disorder: A population-based longitudinal study. Parkinsonism and Related Disorders, 2019, 62, 105-111.	1.1	39
164	Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study. Brain, 2019, 142, 744-759.	3.7	636
165	Brain Glucose Metabolism Heterogeneity in Idiopathic REM Sleep Behavior Disorder and in Parkinson's Disease. Journal of Parkinson's Disease, 2019, 9, 229-239.	1.5	12
166	Progressive Gait Deficits in Parkinson's Disease: A Wearable-Based Biannual 5-Year Prospective Study. Frontiers in Aging Neuroscience, 2019, 11, 22.	1.7	45
167	Early ophthalmologic features of Parkinson's disease: a review of preceding clinical and diagnostic markers. Journal of Neurology, 2019, 266, 2103-2111.	1.8	20
168	Prognosis and Neuropathologic Correlation of Clinical Subtypes of Parkinson Disease. JAMA Neurology, 2019, 76, 470.	4.5	205
169	Cardiovascular autonomic neuropathy and falls in Parkinson disease: a prospective cohort study. Journal of Neurology, 2019, 266, 85-91.	1.8	26

#	ARTICLE	IF	CITATIONS
170	Age and time course of long-term motor and nonmotor complications in Parkinson disease. Neurology, 2019, 92, e148-e160.	1.5	56
171	Genetics of REM Sleep Behavior Disorder. , 2019, , 589-609.		2
172	Biomarkers of Neurodegenerative Disease in Idiopathic RBD. , 2019, , 527-540.		0
173	The Diagnosis of Parkinson's Disease: Current Clinical Practice and Future Trends. , 2019, , 103-116.		1
174	Viewpoint: Developing drugs for levodopaâ€induced dyskinesia in <scp>PD</scp> : Lessons learnt, what does the future hold?. European Journal of Neuroscience, 2019, 49, 399-409.	1.2	11
175	A clinical-anatomical signature of Parkinson's disease identified with partial least squares and magnetic resonance imaging. Neurolmage, 2019, 190, 69-78.	2.1	66
176	Pathological Influences on Clinical Heterogeneity in Lewy Body Diseases. Movement Disorders, 2020, 35, 5-19.	2.2	60
177	Association between REM sleep behavior disorder and impulsive–compulsive behaviors in Parkinson's disease: a systematic review and meta-analysis of observational studies. Journal of Neurology, 2020, 267, 331-340.	1.8	14
178	Time to move beyond genetics towards biomedical data-driven translational genomic research in severe paediatric epilepsies. European Journal of Paediatric Neurology, 2020, 24, 35-39.	0.7	2
179	Predicting severity and prognosis in Parkinson's disease from brain microstructure and connectivity. NeuroImage: Clinical, 2020, 25, 102111.	1.4	26
180	Cognitive impairment in Parkinson's disease: A clinical and pathophysiological overview. Journal of the Neurological Sciences, 2020, 419, 117177.	0.3	20
181	Unsupervised clustering of dopamine transporter <scp>PET</scp> imaging discovers heterogeneity of parkinsonism. Human Brain Mapping, 2020, 41, 4744-4752.	1.9	9
182	Motor/Nonmotor Symptoms and Progression in Patients with Parkinson's Disease: Prevalence and Risks in a Longitudinal Study. Parkinson's Disease, 2020, 2020, 1-13.	0.6	8
183	Effects of Subthalamic Nucleus Deep Brain Stimulation on Facial Emotion Recognition in Parkinson's Disease: A Critical Literature Review. Behavioural Neurology, 2020, 2020, 1-18.	1.1	9
184	Clinical Characterization of Parkinson's Disease Patients With Cognitive Impairment. Frontiers in Neurology, 2020, 11, 731.	1.1	11
185	Gray Matter Alterations in Parkinson's Disease With Rapid Eye Movement Sleep Behavior Disorder: A Meta-Analysis of Voxel-Based Morphometry Studies. Frontiers in Aging Neuroscience, 2020, 12, 213.	1.7	7
186	Association of specific biotypes in patients with Parkinson disease and disease progression. Neurology, 2020, 95, e1445-e1460.	1.5	22
187	Prolonged visual fixation as a surrogate marker of cholinergic deficit in Parkinson's disease: A 2-year follow-up study. Parkinsonism and Related Disorders, 2020, 81, 60-66.	1.1	0

#	Article	IF	CITATIONS
188	Extracellular Vesicles as Nanotherapeutics for Parkinson's Disease. Biomolecules, 2020, 10, 1327.	1.8	19
189	Multiscale classification of heart failure phenotypes by unsupervised clustering of unstructured electronic medical record data. Scientific Reports, 2020, 10, 21340.	1.6	28
190	Comparison of Three Motor Subtype Classifications in de novo Parkinson's Disease Patients. Frontiers in Neurology, 2020, 11, 601225.	1.1	26
191	Cardioselective peripheral noradrenergic deficiency in Lewy body synucleinopathies. Annals of Clinical and Translational Neurology, 2020, 7, 2450-2460.	1.7	16
192	Cognitive Impairment and Blood Pressure Fluctuations. , 2020, , 122-125.		0
193	Association Between REM Sleep Behavior Disorder and Cognitive Dysfunctions in Parkinson's Disease: A Systematic Review and Meta-Analysis of Observational Studies. Frontiers in Neurology, 2020, 11, 577874.	1.1	10
194	Immunization therapies for Parkinson's disease: state of the art and considerations for future clinical trials. Expert Opinion on Investigational Drugs, 2020, 29, 685-695.	1.9	21
195	Serial Dopamine Transporter Imaging of Nigrostriatal Function in Parkinson's Disease With Probable REM Sleep Behavior Disorder. Frontiers in Neuroscience, 2020, 14, 349.	1.4	15
196	REM Sleep Behavior Disorder in Parkinson's Disease: Effects on Cognitive, Psychiatric, and Functional outcomes. Journal of the International Neuropsychological Society, 2020, 26, 894-905.	1.2	13
197	Response to Suzuki et al.: does good sleep reduce early-morning off periods in patients with Parkinson's disease?. Sleep, 2020, 43, .	0.6	0
198	Is It Possible to Conduct a Multi-Arm Multi-Stage Platform Trial in Parkinson's Disease: Lessons Learned from Other Neurodegenerative Disorders and Cancer. Journal of Parkinson's Disease, 2020, 10, 413-428.	1.5	15
199	Is Rapid Eye Movement Sleep Behavior Disorder a Risk Factor for Impulse Control Disorder in Parkinson Disease?. Annals of Neurology, 2020, 88, 759-770.	2.8	10
200	White Matter Hyperintensities Mediate Impact of Dysautonomia on Cognition in Parkinson's Disease. Movement Disorders Clinical Practice, 2020, 7, 639-647.	0.8	32
201	Benign versus malignant Parkinson disease: the unexpected silver lining of motor complications. Journal of Neurology, 2020, 267, 2949-2960.	1.8	26
202	Identifying and predicting Parkinson's disease subtypes through trajectory clustering via bipartite networks. PLoS ONE, 2020, 15, e0233296.	1.1	16
203	Understanding motor control in health and disease: classic single (n = 1) observations. Experimental Brain Research, 2020, 238, 1593-1600.	0.7	8
204	Higher vitamin B12 level at Parkinson's disease diagnosis is associated with lower risk of future dementia. Parkinsonism and Related Disorders, 2020, 73, 19-22.	1.1	10
205	The role of disease duration and severity on novel clinical subtypes of Parkinson disease. Parkinsonism and Related Disorders, 2020, 73, 31-34.	1.1	10

#	Article	IF	CITATIONS
206	<i>Inâ€vivo</i> signatures of neurodegeneration in isolated rapid eye movement sleep behaviour disorder. European Journal of Neurology, 2020, 27, 1285-1295.	1.7	17
207	Clinically relevant connectivity features define three subtypes of Parkinson's disease patients. Human Brain Mapping, 2020, 41, 4077-4092.	1.9	12
208	Early autonomic and cognitive dysfunction in PD, DLB and MSA: blurring the boundaries between α-synucleinopathies. Journal of Neurology, 2020, 267, 3444-3456.	1.8	17
209	Parkinson disease clinical subtypes: key features & Dinical milestones. Annals of Clinical and Translational Neurology, 2020, 7, 1272-1283.	1.7	27
210	Altered activation and connectivity of the supplementary motor cortex at motor initiation in Parkinson's disease patients with freezing. Clinical Neurophysiology, 2020, 131, 2171-2180.	0.7	14
211	Prodromal PD: A new nosological entity. Progress in Brain Research, 2020, 252, 331-356.	0.9	25
212	Sleep in Parkinson's disease: A systematic review and meta-analysis of polysomnographic findings. Sleep Medicine Reviews, 2020, 51, 101281.	3.8	76
213	Does REM sleep behavior disorder change in the progression of Parkinson's disease?. Sleep Medicine, 2020, 68, 190-198.	0.8	29
214	Crossâ€sectional and longitudinal associations between probable rapid eye movement sleep behavior disorder and impulse control disorders in Parkinson's disease. European Journal of Neurology, 2020, 27, 757-763.	1.7	6
215	Fineâ€Mapping of <i>SNCA</i> in Rapid Eye Movement Sleep Behavior Disorder and Overt Synucleinopathies. Annals of Neurology, 2020, 87, 584-598.	2.8	39
216	The Quebec Parkinson Network: A Researcher-Patient Matching Platform and Multimodal Biorepository. Journal of Parkinson's Disease, 2020, 10, 301-313.	1.5	35
217	Rapid Eye Movement Sleep Behavior Disorder and Neurodegenerative Diseases: An Update., 2020, 11, 315.		61
218	Neuropsychiatric symptoms and cognitive abilities over the initial quinquennium of Parkinson disease. Annals of Clinical and Translational Neurology, 2020, 7, 449-461.	1.7	44
219	Diagnosing REM sleep behavior disorder in Parkinson's disease without a gold standard: a latent-class model study. Sleep, 2020, 43, .	0.6	13
220	Facial expressions recognition and discrimination in Parkinson's disease. Journal of Neuropsychology, 2021, 15, 46-68.	0.6	26
221	Increased rapid eye movement density in Chinese patients with Parkinson's disease and RBD. Neurological Sciences, 2021, 42, 961-968.	0.9	4
222	The Pathophysiological Correlates of Parkinson's Disease Clinical Subtypes. Movement Disorders, 2021, 36, 370-379.	2.2	22
223	Immunohistochemical Detection of Synuclein Pathology in Skin in Idiopathic Rapid Eye Movement Sleep Behavior Disorder and Parkinsonism. Movement Disorders, 2021, 36, 895-904.	2.2	31

#	Article	IF	CITATIONS
224	Robust Bayesian Analysis of Early-Stage Parkinson's Disease Progression Using DaTscan Images. IEEE Transactions on Medical Imaging, 2021, 40, 549-561.	5.4	5
225	Clinical Markers May Identify Patients at Risk for Early Parkinson's Disease Dementia: A Prospective Study. American Journal of Alzheimer's Disease and Other Dementias, 2021, 36, 153331752110213.	0.9	2
226	Autonomic dysfunction during sleep in Parkinson's disease. International Review of Movement Disorders, 2021, 1, 251-283.	0.1	0
227	Motor Progression in Early-Stage Parkinson's Disease: A Clinical Prediction Model and the Role of Cerebrospinal Fluid Biomarkers. Frontiers in Aging Neuroscience, 2020, 12, 627199.	1.7	6
228	A Systematic Review of Parkinson's Disease Cluster Analysis Research. , 2021, 12, 1567.		18
230	Abnormal Gray Matter Volume and Functional Connectivity in Parkinson's Disease with Rapid Eye Movement Sleep Behavior Disorder. Parkinson's Disease, 2021, 2021, 1-11.	0.6	9
231	Combined unsupervised-supervised machine learning for phenotyping complex diseases with its application to obstructive sleep apnea. Scientific Reports, 2021, 11, 4457.	1.6	15
232	Complications following REM sleep behavior disorder. Brain and Behavior, 2021, 11, e02129.	1.0	2
234	Probable REM sleep behavior disorder is associated with longitudinal cortical thinning in Parkinson's disease. Npj Parkinson's Disease, 2021, 7, 19.	2.5	14
235	Consistency and Stability of Motor Subtype Classifications in Patients With de novo Parkinson's Disease. Frontiers in Neuroscience, 2021, 15, 637896.	1.4	13
236	Detection of Motor Dysfunction With Wearable Sensors in Patients With Idiopathic Rapid Eye Movement Disorder. Frontiers in Bioengineering and Biotechnology, 2021, 9, 627481.	2.0	6
237	Corneal Confocal Microscopy Identifies Parkinson's Disease with More Rapid Motor Progression. Movement Disorders, 2021, 36, 1927-1934.	2.2	16
238	The α-Synuclein Origin and Connectome Model (SOC Model) of Parkinson's Disease: Explaining Motor Asymmetry, Non-Motor Phenotypes, and Cognitive Decline. Journal of Parkinson's Disease, 2021, 11, 455-474.	1.5	81
239	Delayed orthostatic hypotension in Parkinson's disease. Npj Parkinson's Disease, 2021, 7, 37.	2.5	10
240	Prodromal Parkinson disease subtypes â€" key to understanding heterogeneity. Nature Reviews Neurology, 2021, 17, 349-361.	4.9	171
241	Dopaminergic Correlates of Orthostatic Hypotension in de novo Parkinson's Disease. Journal of Parkinson's Disease, 2021, 11, 665-673.	1.5	1
242	Objective sleep data as predictors of cognitive decline in dementia with Lewy Bodies and Parkinson's disease. Sleep Medicine, 2021, 80, 273-278.	0.8	11
243	REM Sleep Behavior Disorder in Parkinson's Disease: Change in Cognitive, Psychiatric, and Functional Outcomes from Baseline to 16–47-Month Follow-Up. Archives of Clinical Neuropsychology, 2021, , .	0.3	2

#	Article	IF	Citations
244	Early constipation predicts faster dementia onset in Parkinson's disease. Npj Parkinson's Disease, 2021, 7, 45.	2.5	27
245	REM sleep behavioral disorder may be an independent risk factor for orthostatic hypotension in Parkinson's disease. Aging Clinical and Experimental Research, 2022, 34, 159-166.	1.4	4
246	Challenges in the diagnosis of Parkinson's disease. Lancet Neurology, The, 2021, 20, 385-397.	4.9	468
247	Plasma NfL, clinical subtypes and motor progression in Parkinson's disease. Parkinsonism and Related Disorders, 2021, 87, 41-47.	1.1	26
248	Quantitative sensory testing and norepinephrine levels in REM sleep behaviour disorder $\hat{a} \in \hat{a}$ a clue to early peripheral autonomic and sensory dysfunction?. Journal of Neurology, 2022, 269, 923-932.	1.8	5
249	Association of Orthostatic Hypotension With Cerebral Atrophy in Patients With Lewy Body Disorders. Neurology, 2021, 97, e814-e824.	1.5	14
250	Asymmetry at Disease Onset Is Not a Predictor of Parkinson's Disease Progression. Journal of Parkinson's Disease, 2021, 11, 1689-1694.	1.5	4
252	Development and Validation of a Prognostic Model for Cognitive Impairment in Parkinson's Disease With REM Sleep Behavior Disorder. Frontiers in Aging Neuroscience, 2021, 13, 703158.	1.7	4
253	Asymmetric Dopaminergic Dysfunction in Brain-First versus Body-First Parkinson's Disease Subtypes. Journal of Parkinson's Disease, 2021, 11, 1677-1687.	1.5	34
254	Clinical and Dopamine Depletion Patterns in Hyposmia- and Dysautonomia-Dominant Parkinson's Disease. Journal of Parkinson's Disease, 2021, 11, 1-11.	1.5	1
255	Distinct progression patterns across Parkinson disease clinical subtypes. Annals of Clinical and Translational Neurology, 2021, 8, 1695-1708.	1.7	4
256	The Cholinergic Brain in Parkinson's Disease. Movement Disorders Clinical Practice, 2021, 8, 1012-1026.	0.8	42
257	Clinical classification systems and long-term outcome in mid- and late-stage Parkinson's disease. Npj Parkinson's Disease, 2021, 7, 66.	2.5	4
258	Current Update on Clinically Relevant Sleep Issues in Parkinson's Disease: A Narrative Review. Journal of Parkinson's Disease, 2021, 11, 971-992.	1.5	14
259	Paradoxical Cerebral Perfusion in Parkinson's Disease Patients with Orthostatic Hypotension: A Dual-Phase 18F-Florbetaben Positron Emission Tomography Study. Journal of Parkinson's Disease, 2021, 11, 1335-1344.	1.5	4
260	Constipation is Associated with Development of Cognitive Impairment in de novo Parkinson's Disease: A Longitudinal Analysis of Two International Cohorts. Journal of Parkinson's Disease, 2021, 11, 1209-1219.	1.5	29
261	Adverse effects of hypertension, supine hypertension, and perivascular space on cognition and motor function in PD. Npj Parkinson's Disease, 2021, 7, 69.	2.5	15
262	Risk Disclosure in Prodromal Parkinson's Disease. Movement Disorders, 2021, 36, 2833-2839.	2.2	17

#	Article	IF	CITATIONS
263	Cardiac sympathetic burden reflects Parkinson disease burden, regardless of high or low orthostatic blood pressure changes. Npj Parkinson's Disease, 2021, 7, 71.	2.5	9
264	Discovery of Parkinson's disease states and disease progression modelling: a longitudinal data study using machine learning. The Lancet Digital Health, 2021, 3, e555-e564.	5.9	29
265	Cognitive Decline in Parkinson's Disease: A Subgroup of Extreme Decliners Revealed by a Data-Driven Analysis of Longitudinal Progression. Frontiers in Psychology, 2021, 12, 729755.	1.1	4
266	Deciphering the Role of Nanoparticle-based Treatment for Parkinson's Disease. Current Drug Metabolism, 2021, 22, 550-560.	0.7	8
267	Increased Mortality in Young-Onset Parkinson's Disease. Journal of Movement Disorders, 2021, 14, 214-220.	0.7	9
268	Exploration of Parkinson's Disease Symptomatology Subtypes From the Caregiver Perspective: Implications for Caregiver Burden, Depression, and Anxiety. Journal of Geriatric Psychiatry and Neurology, 2022, 35, 663-670.	1.2	3
269	Rates of neuromuscular excitation during cycling in Parkinson's disease compared to healthy young and older adults. Clinical Biomechanics, 2021, 90, 105488.	0.5	0
270	Longitudinal clustering analysis and prediction of Parkinson's disease progression using radiomics and hybrid machine learning. Quantitative Imaging in Medicine and Surgery, 2022, 12, 906-919.	1.1	20
271	Alteration of brain structural connectivity in progression of Parkinson's disease: A connectome-wide network analysis. NeuroImage: Clinical, 2021, 31, 102715.	1.4	16
272	Morbidity, Mortality, and Conversion to Neurodegenerative Diseases in Patients with REM Sleep Behavior Disorder and REM Sleep without Atonia. Neuroepidemiology, 2021, 55, 141-153.	1.1	2
273	General approach to patients with autonomic dysfunction in Parkinson's disease. International Review of Movement Disorders, 2021, 1, 19-39.	0.1	2
274	Neuropsychological Aspects: Cognition in RBD. , 2019, , 491-507.		2
275	Neuropsychological Aspects: Impulse-Control Disorders and Other Neuropsychiatric Features in RBD. , 2019, , 509-525.		2
276	Diagnosing mild cognitive impairment in Parkinson's disease: which tests perform best in the Italian population?. Neurological Sciences, 2017, 38, 1461-1468.	0.9	4
277	Multi-layer Trajectory Clustering: a Network Algorithm for Disease Subtyping. Biomedical Physics and Engineering Express, 2020, 6, 065003.	0.6	5
280	An RNN Architecture with Dynamic Temporal Matching for Personalized Predictions of Parkinson's Disease. , 2017, , 198-206.		77
281	Patient Subtyping via Time-Aware LSTM Networks. , 2017, , .		333
282	GDF15/MIC1 and MMP9 Cerebrospinal Fluid Levels in Parkinson's Disease and Lewy Body Dementia. PLoS ONE, 2016, 11, e0149349.	1.1	29

#	Article	IF	Citations
283	Subtyping of Parkinson's Disease - Where Are We Up To?. , 2019, 10, 1130.		50
284	Emerging Concepts of Motor Reserve in Parkinson's Disease. Journal of Movement Disorders, 2020, 13, 171-184.	0.7	30
285	Functional Connectomics and Disease Progression in Drugâ€NaÃ⁻ve Parkinson's Disease Patients. Movement Disorders, 2021, 36, 1603-1616.	2.2	27
286	Constipation Predicts Cognitive Decline in Parkinson's Disease: Results from the COPPADIS Cohort at 2-Year Follow-up and Comparison with a Control Group. Journal of Parkinson's Disease, 2022, 12, 315-331.	1.5	10
287	Clinical and Dopamine Transporter Imaging Trajectories in a Cohort of Parkinson's Disease Patients with <scp>GBA</scp> Mutations. Movement Disorders, 2022, 37, 106-118.	2.2	13
288	Subtype Identification of Parkinson's Disease Using Sparse Canonical Correlation and Clustering Analysis of Multimodal Neuroimaging. Communications in Computer and Information Science, 2019, , 126-136.	0.4	O
292	The different syndromes in Parkinson's disease: an overview., 2020,, 235-249.		O
293	Determinants of quality of life in Parkinson's disease: a perspective of novel clinical subtypes. Annals of Clinical and Translational Neurology, 2021, 8, 2174-2183.	1.7	1
294	REM sleep behavior in Parkinson disease: Frequent, particularly with higher age. PLoS ONE, 2020, 15, e0243454.	1.1	14
295	Neuropathological evidence of body-first vs. brain-first Lewy body disease. Neurobiology of Disease, 2021, 161, 105557.	2.1	72
298	GrundsÃæe der Ergotherapie. , 2021, , 27-38.		0
299	Independent effect of neurogenic orthostatic hypotension on mild cognitive impairment in Parkinson's disease. Clinical Autonomic Research, 2022, 32, 43-50.	1.4	6
300	The role of frailty in Parkinson's disease: a cross-sectional study. Journal of Neurology, 2022, 269, 3006-3014.	1.8	7
301	The effect of Non-Motor symptoms on Health-Related quality of life in patients with young onset Parkinson's Disease: A single center Vietnamese Cross-Sectional study. Clinical Parkinsonism & Related Disorders, 2021, 5, 100118.	0.5	4
302	Correlation of Dopaminergic Denervation and the Progression of Autonomic Dysfunctions in Different Clinical Subtypes of Parkinson's Disease. Parkinson's Disease, 2021, 2021, 1-5.	0.6	2
303	Brain Neuroimaging of Rapid Eye Movement Sleep Behavior Disorder in Parkinson's Disease: A Systematic Review. Journal of Parkinson's Disease, 2022, 12, 69-83.	1.5	3
305	Risk Factors for Phenoconversion in <scp>Rapid Eye Movement</scp> Sleep Behavior Disorder. Annals of Neurology, 2022, 91, 404-416.	2.8	27
306	Body-first Parkinson's disease and variant Creutzfeldt–Jakob disease – similar or different?. Neurobiology of Disease, 2022, 164, 105625.	2.1	2

#	Article	IF	CITATIONS
307	Parkinson's Disease Diagnosis and Severity Prediction with Machine Learning Techniques., 2021,,.		0
308	Evolution of Prodromal Multiple System Atrophy from REM Sleep Behavior Disorder: A Descriptive Study. Journal of Parkinson's Disease, 2022, 12, 983-991.	1.5	3
309	Parkinson's Disease Subtyping Using Clinical Features and Biomarkers: Literature Review and Preliminary Study of Subtype Clustering. Diagnostics, 2022, 12, 112.	1.3	12
310	REM sleep without atonia and vestibular-evoked myogenic potentials: clinical brainstem dysfunction in early-stage Parkinson's disease and isolated REM sleep behavior disorder. Sleep Medicine, 2022, 89, 122-129.	0.8	8
312	Neuropathological substrates of cognition in Parkinson's disease. Progress in Brain Research, 2022, 269, 177-193.	0.9	4
313	A Hybrid Machine Learning and Network Analysis Approach Reveals Two Parkinson's Disease Subtypes from 115 RNA-Seq Post-Mortem Brain Samples. International Journal of Molecular Sciences, 2022, 23, 2557.	1.8	3
314	Two-Channel Portable Biopotential Recording System Can Detect REM Sleep Behavioral Disorder: Validation Study with a Comparison of Polysomnography. Parkinson's Disease, 2022, 2022, 1-5.	0.6	2
315	Multimodal brain and retinal imaging of dopaminergic degeneration in Parkinson disease. Nature Reviews Neurology, 2022, 18, 203-220.	4.9	44
316	Initiation and progression of α-synuclein pathology in Parkinson's disease. Cellular and Molecular Life Sciences, 2022, 79, 210.	2.4	33
317	Sleep and Autonomic Manifestations in Parkinson's Disease Complicated With Probable Rapid Eye Movement Sleep Behavior Disorder. Frontiers in Neuroscience, 2022, 16, 874349.	1.4	3
318	Gender differences in dopaminergic system dysfunction in de novo Parkinson's disease clinical subtypes. Neurobiology of Disease, 2022, 167, 105668.	2.1	11
319	Validity and Reliability of the Persian Version of Parkinson's Disease Sleep Scale-2. Parkinson's Disease, 2021, 2021, 1-5.	0.6	0
320	Zonisamide for the Efficacy of Sleep Abnormality in Parkinson's Disease (ZEAL Study): A Protocol for Randomized Controlled Trials. Frontiers in Neurology, 2021, 12, 741307.	1.1	1
321	Parkinson's Disease Symptoms Associated with Developing On-State Axial Symptoms Early after Subthalamic Deep Brain Stimulation. Diagnostics, 2022, 12, 1001.	1.3	1
322	Data-Driven Subtyping of Parkinson's Using Acoustic Analysis of Sustained Vowels and Cluster Analysis: Findings in the Parkinson's Voice Initiative Study. SN Computer Science, 2022, 3, 1.	2.3	2
330	Efficacy of Traditional Herbal Medicine Treatment Based on Pattern Identification for Idiopathic Parkinson's Disease: A Protocol for Systematic Review and Meta-Analysis. Evidence-based Complementary and Alternative Medicine, 2022, 2022, 1-5.	0.5	2
331	Combining biomarkers for prognostic modelling of Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 707-715.	0.9	9
332	Clinical Aspects of the Differential Diagnosis of Parkinson's Disease and Parkinsonism. Journal of		

#	Article	IF	CITATIONS
334	Characterization of Parkinson's Disease Subtypes and Related Attributes. Frontiers in Neurology, 2022, 13, .	1.1	2
335	Brain atrophy pattern in de novo Parkinson's disease with probable RBD associated with cognitive impairment. Npj Parkinson's Disease, 2022, 8, .	2.5	9
337	Differential impact of individual autonomic domains on clinical outcomes in Parkinson's disease. Journal of Neurology, 2022, 269, 5510-5520.	1.8	9
338	Association of Concurrent Olfactory Dysfunction and Probable Rapid Eye Movement Sleep Behavior Disorder with Early Parkinson's Disease Progression. Movement Disorders Clinical Practice, 2022, 9, 909-919.	0.8	2
339	Semiparametric regression modeling of the global percentile outcome. Journal of Statistical Planning and Inference, 2023, 222, 149-159.	0.4	1
340	Optimal Local Explainer Aggregation for Interpretable Prediction. Proceedings of the AAAI Conference on Artificial Intelligence, 2022, 36, 12000-12007.	3.6	2
341	Exploration of whether socioeconomic factors affect the results of priority setting partnerships: updating the top 10 research priorities for the management of Parkinson's in an international setting. BMJ Open, 2022, 12, e049530.	0.8	2
342	Deep phenotyping for precision medicine in Parkinson's disease. DMM Disease Models and Mechanisms, 2022, 15, .	1.2	5
343	Systematic review of dataâ€driven cognitive subtypes in Parkinson disease. European Journal of Neurology, 0, , .	1.7	5
344	A survey of deep learning techniques based Parkinson's disease recognition methods employing clinical data. Expert Systems With Applications, 2022, 208, 118045.	4.4	15
345	Age Cutoff for Earlyâ€Onset Parkinson's Disease: Recommendations from the International Parkinson and Movement Disorder Society Task Force on Early Onset Parkinson's Disease. Movement Disorders Clinical Practice, 2022, 9, 869-878.	0.8	26
346	Diagnosing Parkinson's Disease: its evolution to future. , 2022, , .		1
347	Identifying and validating subtypes of Parkinson's disease based on multimodal MRI data via hierarchical clustering analysis. Frontiers in Human Neuroscience, 0, 16, .	1.0	4
348	Neuroprotective Trials in REM Sleep Behavior Disorder. Neurology, 2022, 99, 19-25.	1.5	20
350	REM Sleep Behaviour Disorder in Parkinson's disease: A survey based study. Canadian Journal of Neurological Sciences, 0, , 1-21.	0.3	0
351	Multi-predictor modeling for predicting early Parkinson's disease and non-motor symptoms progression. Frontiers in Aging Neuroscience, 0, 14, .	1.7	1
352	Who to Enroll in Parkinson Disease Prevention Trials?. Neurology, 2022, 99, 26-33.	1.5	6
353	Sleep stability in isolated rapid eye movement sleep behavior disorder, Parkinson's disease, and dementia with Lewy bodies. Acta Neurologica Scandinavica, 2022, 146, 545-552.	1.0	2

#	ARTICLE	IF	CITATIONS
354	A bibliometric analysis of neuroimaging biomarkers in Parkinson disease based on Web of Science. Medicine (United States), 2022, 101, e30079.	0.4	3
356	Selected autonomic signs and symptoms as risk markers for phenoconversion and functional dependence in prodromal Parkinson's disease. Clinical Autonomic Research, 0, , .	1.4	1
357	Subgrouping and structural brain connectivity of Parkinson's disease – past studies and future directions. Neuroscience Informatics, 2022, 2, 100100.	2.8	4
358	Progressive autonomic failure. , 2022, , 297-337.		0
359	Mechanisms of development of constipation in Parkinson's disease and therapeutic approaches. Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova, 2022, 122, 21.	0.1	0
360	Biomarker characterization of clinical subtypes of Parkinson Disease. Npj Parkinson's Disease, 2022, 8, .	2.5	6
361	Mild cognitive impairment is associated with poor gait performance in patients with Parkinsonâ $\in$ <sup>™</sup> s disease. Frontiers in Aging Neuroscience, 0, 14, .	1.7	1
363	Predictors of anxiety in Parkinson's disease: results from a 3-year longitudinal cohort study. Neurological Sciences, 2023, 44, 547-556.	0.9	2
364	Effect of Lower Limb vs. Abdominal Compression on Mobility in Orthostatic Hypotension: A Single-Blinded, Randomized, Controlled, Cross-Over Pilot Study in Parkinson's Disease. Journal of Parkinson's Disease, 2022, 12, 2531-2541.	1.5	3
365	Genetically-informed prediction of short-term Parkinson's disease progression. Npj Parkinson's Disease, 2022, 8, .	2.5	3
366	Risk factors for rapid eye-movement sleep-related behavioral disorders (RBDs): A systematic review and a meta-analysis. General Hospital Psychiatry, 2022, 79, 118-127.	1.2	5
367	Molecular imaging evidence in favor or against PDD and DLB overlap. , 2023, , 275-295.		1
368	Stability of motor-nonmotor subtype in early-stage Parkinson's disease. Frontiers in Aging Neuroscience, 0, 14, .	1.7	2
369	Classification of Parkinson's disease motor phenotype: a machine learning approach. Journal of Neural Transmission, 2022, 129, 1447-1461.	1.4	0
370	Deep brain stimulation in Early Onset Parkinson's disease. Frontiers in Neurology, 0, 13, .	1.1	3
371	Regional cortical hypoperfusion and atrophy correlate with striatal dopaminergic loss in Parkinson's disease: a study using arterial spin labeling MR perfusion. Neuroradiology, 0, , .	1.1	1
372	A Combined Panel of Salivary Biomarkers in de novo Parkinson's Disease. Annals of Neurology, 2023, 93, 446-459.	2.8	14
373	Subtyping of early-onset Parkinson's disease using cluster analysis: A large cohort study. Frontiers in Aging Neuroscience, 0, 14, .	1.7	4

#	Article	IF	CITATIONS
374	Reward insensitivity is associated with dopaminergic deficit in rapid eye movement sleep behaviour disorder. Brain, 2023, 146, 2502-2511.	3.7	5
375	A Novel Approach to Parkinson's Disease Progression Evaluation Using Convolutional Neural Networks. International Journal of Software Innovation, 2022, 11, 1-26.	0.3	0
376	A postmortem study suggests a revision of the dual-hit hypothesis of Parkinson's disease. Npj Parkinson's Disease, 2022, 8, .	2.5	39
377	Nomogram to Predict the Probability of Functional Dependence in Early Parkinson's Disease. Journal of Parkinson's Disease, 2023, 13, 49-55.	1.5	2
378	Baroreflex-sympathoneural dysfunction characterizes at-risk individuals with preclinical central Lewy body diseases. Clinical Autonomic Research, 0, , .	1.4	1
379	Microbiome and Metabolome Insights into the Role of the Gastrointestinal–Brain Axis in Parkinson's and Alzheimer's Disease: Unveiling Potential Therapeutic Targets. Metabolites, 2022, 12, 1222.	1.3	6
380	Identification and prediction of Parkinson's disease subtypes and progression using machine learning in two cohorts. Npj Parkinson's Disease, 2022, 8, .	2.5	14
381	Alterations of Regional Homogeneity in Parkinson's Disease with Rapid Eye Movement Sleep Behavior Disorder. Neuropsychiatric Disease and Treatment, 0, Volume 18, 2967-2978.	1.0	O
382	RBDtector: an open-source software to detect REM sleep without atonia according to visual scoring criteria. Scientific Reports, 2022, 12, .	1.6	3
383	Caudate-anchored cognitive connectivity pursuant to orthostatic hypotension in early Parkinson's disease. Scientific Reports, 2022, 12, .	1.6	1
384	Sleep and wakefulness disturbances in Parkinson's disease: A meta-analysis on prevalence and clinical aspects of REM sleep behavior disorder, excessive daytime sleepiness and insomnia. Sleep Medicine Reviews, 2023, 68, 101759.	3.8	23
385	Narrative Review Concerning the Clinical Spectrum of Ophthalmological Impairments in Parkinson's Disease. Neurology International, 2023, 15, 140-161.	1.3	2
386	Brain Degeneration in Synucleinopathies Based on Analysis of Cognition and Other Nonmotor Features: A Multimodal Imaging Study. Biomedicines, 2023, 11, 573.	1.4	1
387	A machine learning approach to predict quality of life changes in patients with Parkinson's Disease. Annals of Clinical and Translational Neurology, 2023, 10, 312-320.	1.7	4
388	The relationship between serum neurofilament light chain and glial fibrillary acidic protein with the <scp>REM</scp> sleep behavior disorder subtype of Parkinson's disease. Journal of Neurochemistry, 2023, 165, 268-276.	2.1	6
389	Machine learning within the Parkinson $\hat{a} \in \mathbb{R}^{\infty}$ s progression markers initiative: Review of the current state of affairs. Frontiers in Aging Neuroscience, 0, 15, .	1.7	9
390	The definition of precision medicine in neurodegenerative disorders and the one disease-many diseases tension. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2023, , 3-20.	1.0	1
391	α-Synuclein induces prodromal symptoms of Parkinson's disease via activating TLR2/MyD88/NF-κB pathway in Schwann cells of vagus nerve in a rat model. Journal of Neuroinflammation, 2023, 20, .	3.1	6

#	Article	IF	CITATIONS
393	Two-year clinical progression in focal and diffuse subtypes of Parkinson's disease. Npj Parkinson's Disease, 2023, 9, .	2.5	6
394	Artificial intelligence-based clustering and characterization of Parkinson's disease trajectories. Scientific Reports, 2023, 13, .	1.6	3
395	A progression analysis of motor features in Parkinson's disease based on the mapper algorithm. Frontiers in Aging Neuroscience, 0, $15$ , .	1.7	0
396	Staging Parkinson's Disease According to the MNCD (Motor/Non-motor/Cognition/Dependency) Classification Correlates with Disease Severity and Quality of Life. Journal of Parkinson's Disease, 2023, 13, 379-402.	1.5	0
397	Genetic testing for Parkinson's disease in clinical practice. Journal of Neural Transmission, 2023, 130, 777-782.	1.4	4
399	Severity of <scp>REM</scp> sleep without atonia correlates with measures of cognitive impairment and depressive symptoms in <scp>REM</scp> sleep behaviour disorder. Journal of Sleep Research, 2023, 32, .	1.7	4
400	Data-driven subtyping of Parkinson's disease: comparison of current methodologies and application to the Bochum PNS cohort. Journal of Neural Transmission, 0, , .	1.4	0
402	The brain-first vs. body-first model of Parkinson's disease with comparison to alternative models. Journal of Neural Transmission, 2023, 130, 737-753.	1.4	10
403	Parkinson's disease patients combined with constipation tend to have higher serum expression of microRNA 29c, prominent neuropsychiatric disorders, possible RBD conversion, and a substandard quality of life. Neurological Sciences, 0, , .	0.9	0
408	Fluid and Biopsy Based Biomarkers in Parkinson's Disease. Neurotherapeutics, 2023, 20, 932-954.	2.1	6
411	Access to device-aided therapies in advanced Parkinson's disease: navigating clinician biases, patient preference, and prognostic uncertainty. Journal of Neural Transmission, 0, , .	1.4	2
413	Cognitive impairment and dementia in young onset Parkinson's disease. Journal of Neurology, 2023, 270, 5793-5812.	1.8	2
445	Estimating motor progression trajectory pursuant to temporal dynamic status of cardiac denervation in Parkinson's disease. Journal of Neurology, 2024, 271, 2019-2030.	1.8	0